Albireo: Strong Phase 3 Data Foretells More Upside
- Sales for Bylvay's first approved indication is increasing. The company recently posted superb data for an orphan disease known as Alagille Syndrome.
- 10/12/2022
|
Albireo (ALBO) Up on Results From Alagille Syndrome Study
- Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.
- 10/12/2022
|
Albireo's stock is up 10% on plans to seek FDA approval for drug for rare disorder
- Shares of Albireo Pharma Inc. ALBO, +6.86% gained 10.4% in premarket trading on Tuesday after the company said it is seeking Food and Drug Administration approval to use its medication Bylvay as a treatment for Alagille syndrome, a rare inherited disorder that can result in liver damage. Albireo said a Phase 3 clinical trial evaluating the drug met its primary endpoint and a key secondary endpoint.
- 10/11/2022
|
Albireo Pharma: Assessing The Sagard Deal
- Albireo Pharma, Inc. is expanding its Bylvay label for two other rare liver conditions, biliary atresia and Alagille syndrome. The company is poised to report topline data for the Phase 3 (ASSERT) trial for Alagille syndrome this Fall.
- 10/03/2022
|
Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?
- Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 09/23/2022
|
Albireo to Participate in Upcoming Investor Conferences
- BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in upcoming investor conferences:
- 09/01/2022
|
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2022 Results - Earnings Call Transcript
- Albireo Pharma, Inc. (NASDAQ:ALBO ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Ron Cooper - CEO, President & Director Pamela Stephenson - Chief Commercial Officer Simon Harford - CFO & Treasurer Conference Call Participants Ritu Baral - Cowen and Company Eun Yang - Jefferies Lachlan Hanbury-Brown - William Blair & Company Ed Arce - H.C. Wainwright & Co. Andreas Argyrides - Wedbush Securities Brian Skorney - Robert W.
- 08/15/2022
|
Albireo Pharma (ALBO) Reports Q2 Loss, Misses Revenue Estimates
- Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/15/2022
|
Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?
- Here is how Albireo Pharma (ALBO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
- 08/11/2022
|
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
- Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
- 07/25/2022
|
Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
- Albireo promotes international sales of its approved product Bylvay for the treatment of the extremely rare and orphan disease PFIC. Investors do not yet appreciate the full potential of Bylvay, which presents a good entry opportunity for investors.
- 07/22/2022
|
Albireo to Present at the William Blair Biotech Focus Conference 2022
- BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Biotech Focus Conference July 12-13, 2022. Ron Cooper, President and Chief Executive Officer, will take part in a fireside chat during the conference. Ron and Simon Harford, Chief Financial Officer, will also host meetings during the conference.
- 06/30/2022
|
Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
- – Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat)
- 06/07/2022
|
Albireo to Participate at Upcoming Investor Conferences
- BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer will be presenting at the following investor conferences:
- 06/02/2022
|
Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022
- BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright Global Life Science Conference May 23-26, 2022. Simon Harford, Chief Financial Officer, will be presenting on Wednesday, May 25, which will be available on-demand on the Albireo Investors page ir.albireopharma.com. Simon and Pamela Stephenson, Chief Commercial Officer, will host meetings with investors.
- 05/19/2022
|
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q1 2022 Results - Earnings Call Transcript
- Albireo Pharma, Inc. (NASDAQ:ALBO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director-LifeSci Advisors, LLC Ron Cooper - President & Chief Executive Officer Pamela Stephenson - Chief Commercial Officer Simon Harford - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Eun Yang - Jefferies Brian Skorney - Baird Andreas Argyrides - Wedbush Securities Ed Arce - H.C. Wainwright Operator Good afternoon, and welcome to the Albireo Pharma First Quarter 2022 Earnings Call.
- 05/16/2022
|
Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates
- Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/16/2022
|
Albireo to Report Q1 2022 Financial Results on May 16
- Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET
- 05/09/2022
|
Albireo: A Speculative Play With Upside
- The lead medicine (Bylvay) is already approved to treat an orphan disease known as progressive familial intrahepatic cholestasis. Leveraging a prudent growth strategy, Albireo is aggressively expanding Bylvay's label for other rare conditions.
- 05/03/2022
|
Is a Surprise Coming for Albireo Pharma (ALBO) This Earnings Season?
- Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/28/2022
|
Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.
- The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021.
- 02/01/2022
|
Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
- After the approval of Odevixibat in the PFIC, Albireo successfully transforms into a commercial company capable of generating profits.
- 01/31/2022
|
Wall Street Analysts Predict an 184% Upside in Albireo Pharma (ALBO): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 183.9% in Albireo Pharma (ALBO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/12/2022
|
Albireo Pharma Stock (ALBO): Why The Price Increased
- The stock price of Albireo Pharma Inc (NASDAQ: ALBO) increased by 1.55% in the most recent trading session. This is why it happened.
- 01/06/2022
|
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
- Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in programs and the reemergence of variant strains.
- 12/27/2021
|
Albireo: Reasons For A Successful Transformation Into A Commercial Company
- Albireo developed Odevixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications.
- 11/24/2021
|
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2021 Results - Earnings Call Transcript
- Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2021 Results - Earnings Call Transcript
- 11/04/2021
|
Albireo Pharma (ALBO) Reports Q3 Loss, Lags Revenue Estimates
- Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Albireo to Report Third Quarter 2021 Financial Results on November 4
- — Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —
- 10/28/2021
|
Albireo to Showcase New Data at AASLD The Liver Meeting® 2021
- – Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases –
- 10/15/2021
|
Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan
- – Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia –
- 10/12/2021
|
Albireo Recognizes PFIC Awareness Day 2021
- BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC). Established in 2019, PFIC Awareness Day aims to highlight the impact of this disease on patients and families, and to call for new levels of support, including research, advocacy, education and opportunities to connect and share information.
- 10/05/2021
|
Albireo Announces Bylvay® (odevixibat) Now Available in Germany
- – Listed on the German national price list and all pharmacy software programs –
- 09/15/2021
|
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo's common stock and restricted stock units representing the opportunity to acquire 3,500 shares of Albireo's common stock. The exercise price for the inducement grants is $29.50 per share, the closing price of Albireo's common stock on September 7, 2021, the grant date, and were granted as inducements material to the employee's acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee's continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee's start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo's 2020 Inducement Equity Incentive Plan.
- 09/08/2021
|
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)
- – Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC –
- 09/08/2021
|
Albireo Pharma Sells Bylvay-Associated PRV For $105M
- Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).
- 09/07/2021
|
Albireo to Present at Upcoming Investor Conferences
- BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company's management team will be presenting at the following investor conferences:
- 09/02/2021
|
Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation
- Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation
- 08/24/2021
|
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region
- – Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –
- 08/18/2021
|
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2021 Results - Earnings Call Transcript
- Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2021 Results - Earnings Call Transcript
- 08/07/2021
|
Albireo Reports Q2 Financial Results and Business Update
- – Bylvay TM (odevixibat) approved in U.S. & EU as o nly once-daily drug indicated for patients with PFIC –
- 08/05/2021
|
Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
- BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at 3:30 p.m. ET.
- 08/03/2021
|
Albireo to Report Second Quarter 2021 Financial Results on August 5
- — Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —
- 07/29/2021
|
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
- Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.
- 07/21/2021
|
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
- Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC). PFIC afflicts children with severe, progressive liver disease.
- 07/21/2021
|
MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
- – Only once-daily drug indicated for the treatment of pruritus in PFIC –
- 07/20/2021
|
Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
- – Only once-daily drug indicated for the treatment of pruritus in PFIC –
- 07/20/2021
|
Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease
- The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi).
- 07/19/2021
|
Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)
- – First approval in the world of Bylvay for the treatment of PFIC –
- 07/19/2021
|
Albireo to Present at the William Blair Biotech Focus Conference 2021
- BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, at 11:00 a.m. EDT.
- 07/08/2021
|
Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study
- Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of A3907 in adult liver disease. Data will be presented at the EASL International Liver Congress 2021.
- 06/21/2021
|
Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress
- – Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters –
- 06/21/2021
|
Albireo to Showcase New Data at the EASL International Liver Congress™ 2021
- – Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) –
- 06/10/2021
|
New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC
- – Data being presented show long-term benefits of Bylvay in children with PFIC –
- 06/03/2021
|
Mirum Is Undervalued Despite Expected Tough Competition
- Mirum Is Undervalued Despite Expected Tough Competition
- 06/01/2021
|
Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor Conferences
- BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of fireside chats at both the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, at 9:30 a.m. EDT and William Blair's 41st Annual Growth Stock Conference on Thursday, June 3, at 12:40 p.m. EDT. Members of the management team will also host meetings with investors June 1-3.
- 05/26/2021
|
Albireo's Bylvay Wins Positive Opinion from EMA For Rare Pediatric Liver Disease
- European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients aged six months or older. PFIC is a rare, life-threatening liver disease, and only about half of the children affected by the disease survive beyond the age of 10 years.
- 05/21/2021
|
Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
- – Bylvay has the potential to become first approved drug to treat all forms of PFIC –
- 05/21/2021
|
Albireo to Showcase New Data at 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
- - PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC -
- 05/19/2021
|
Mirum: Rare Disease Play With Upcoming Catalysts
- Mirum: Rare Disease Play With Upcoming Catalysts
- 05/18/2021
|
Albireo Pharma (ALBO) CEO Ron Cooper on Q1 2021 Results - Earnings Call Transcript
- Albireo Pharma (ALBO) CEO Ron Cooper on Q1 2021 Results - Earnings Call Transcript
- 05/08/2021
|
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo's common stock. The stock options are exercisable at a price of $30.37 per share, the closing price of Albireo's common stock on May 4, 2021, the grant date, and were granted as inducements material to the employee's acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee's continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee's start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo's 2020 Inducement Equity Incentive Plan.
- 05/07/2021
|
Albireo Reports Q1 Financial Results and Business Update
- – Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU–
- 05/06/2021
|
Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
- Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
- 04/26/2021
|
Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
- – Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs –
- 04/13/2021
|
Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
- BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15. Albireo executives taking part will include Ron Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer. The team will participate in a fireside chat on April 13 at 9:30 a.m. ET, which will be available on-demand on the Albireo Media & Investors page at ir.albireopharma.com, as well as hosting meeting with investors throughout the conference.
- 04/06/2021
|
Albireo Announces First Patients Dosed in Two New Studies
- – Dosed first patients in Phase 1 study with new product candidate A3907 –
- 03/25/2021
|
Albireo Spotlights Global Patient Communities on Rare Disease Day
- – Calls to unite global communities affected by rare diseases –
- 02/26/2021
|
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2020 Results - Earnings Call Transcript
- Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2020 Results - Earnings Call Transcript
- 02/25/2021
|
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
- – NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –
- 02/25/2021
|
Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
- BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation in the upcoming Cowen 41st Annual Health Care Conference March 1-4, 2021. Ron Cooper, President and Chief Executive Officer of Albireo, will take part in the New Drug Launches Panel on Wednesday, March 3, 2021 at 10:20am ET. Members of the management team will also host meetings with investors on March 2.
- 02/23/2021
|
Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
- Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET
- 02/18/2021
|
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo's common stock. The stock options are exercisable at a price of $38.39 per share, the closing price of Albireo's common stock on February 16, 2021, the grant date, and were granted as inducements material to the employee's acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee's continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee's start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo's 2020 Inducement Equity Incentive Plan.
- 02/17/2021
|
Albireo Presents Odevixibat Commercialization Road to $1 Billion
- – Company outlining large global rare cholestatic liver disease opportunity –
- 02/11/2021
|
Albireo Pharma: De-Risked Small-Cap Biotech Ready For Commercialization
- Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC) is expected in the second half of 2021.
- 01/25/2021
|
Albireo Recognizes International Alagille Syndrome Awareness Day 2021
- Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases
- 01/22/2021
|
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo's common stock. The stock options are exercisable at a price of $37.22 per share, the closing price of Albireo's common stock on January 11, 2021, the grant date, and were granted as inducements material to the employee's acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee's continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee's start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo's 2020 Inducement Equity Incentive Plan.
- 01/14/2021
|
Albireo to Host Virtual Investor Commercial Day 2021
- BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST.
- 01/07/2021
|
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo's common stock. The stock options are exercisable at a price of $36.98 per share, the closing price of Albireo's common stock on January 4, 2021, the grant date, and were granted as inducements material to the employee's acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee's continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee's start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo's 2020 Inducement Equity Incentive Plan.
- 01/06/2021
|
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo's common stock. The stock options are exercisable at a price of $39.77 per share, the closing price of Albireo's common stock on December 9, 2020, the grant date, and were granted as inducements material to the employee's acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee's continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee's start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo's 2020 Inducement Equity Incentive Plan.
- 12/11/2020
|
Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
- - Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -
- 12/08/2020
|
New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease
- - PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -
- 11/13/2020
|
Albireo Reports Q3 2020 Financial Results and Provides Business Update
- - P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -
- 11/05/2020
|
Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
- Albireo reports positive data from Phase 3 trial. Jazz Pharmaceuticals inks new cancer deal with Redx Pharma.
- 09/11/2020
|
Albrireo Therapeutics (ALBO) Investor Presentation - Slideshow
|
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma
- 08/21/2020
|
Albireo Down on Unimpressive Data From Mid-Stage NASH Study
- Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.
- 08/19/2020
|
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
- 08/19/2020
|
Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
- ‒ Achieved primary endpoint ‒ ‒ Unremarkable results in key NASH measures ‒ ‒ Company discontinuing further development ‒BOSTON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced topline results from the Phase 2 proof- of-concept clinical trial evaluating elobixibat, its ileal bile acid transporter (IBAT) inhibitor currently approved in Japan for chronic constipation, for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Following promising results in preclinical studies, the Phase 2 study achieved the primary endpoint of reduction of low-density lipoprotein cholesterol (LDL-C) but did not achieve proof-of-concept for other key NASH measures.Elobixibat achieved the primary endpoint of a reduction in LDL-C with a clinically meaningful effect of -20.5 mg/dL in serum LDL-C compared to -11.1 mg/dL, elobixibat vs. placebo (p<0.022). These reductions were in addition to lipid lowering treatment where 56.5% of the elobixibat and 45.8% of the placebo patients were on stable lipid lowering therapy at baseline. Liver fat reduction in the elobixibat group was -2.6% as measured by MRI PDFF. The baseline alanine aminotransferase (ALT) levels were within the normal range and there was no meaningful change observed in the study. Overall elobixibat was well tolerated, with adverse event incidence similar to placebo and with no serious adverse events or discontinuations due to treatment. The study showed an acceptable gastrointestinal tolerability with 3 of 23 elobixibat patients reporting mild to moderate transient diarrhea attributable to drug treatment. The proof-of-concept Phase 2, multicenter, placebo-controlled trial enrolled 47 patients across 15 U.S. sites, and was designed to assess the safety and efficacy of a once-daily 5 mg dose of elobixibat over 16 weeks in adult patients with biopsy-confirmed NASH or a diagnosis of suspected NAFLD or NASH based on metabolic syndrome definitions. The primary endpoint was change from baseline in LDL-C. Secondary endpoints included change in liver fat by imaging, and in ALT and aspartate aminotransferase levels. Exploratory endpoints included measures of glucose and insulin homeostasis, which are biomarkers for inflammation and fibrosis.“We wanted to investigate the potential of elobixibat in NASH and allocated minimal resources to an exploratory Phase 2 study. Based on the results of this study, we have made the decision not to pursue further development of elobixibat in NASH,” said Ron Cooper, President and Chief Executive Officer of Albireo. “Our main focus continues to be on odevixibat in rare pediatric liver diseases and we look forward to our Phase 3 topline data in the coming weeks.”Albireo is focused and remains on track with several milestones for the remainder of 2020, including topline results from the PEDFIC 1 pivotal Phase 3 trial of odevixibat in progressive familial intrahepatic cholestasis (PFIC) in the coming weeks, potential regulatory approval, issuance of a rare pediatric disease priority review voucher and odevixibat launch anticipated in the second half of 2021. Other anticipated events include initiation of a pivotal Phase 3 trial of odevixibat in Alagille syndrome by the end of 2020, and continued enrollment of patients in the BOLD pivotal Phase 3 trial of odevixibat in biliary atresia. Albireo also continues to progress development of a new preclinical candidate and expects to complete IND-enabling studies this year.About Elobixibat Elobixibat is a first-in-class, once-daily, oral ileal bile acid transporter (IBAT) inhibitor and is approved in Japan for the treatment of patients with chronic constipation (excluding constipation caused by organic disease). It is marketed and sold in Japan under the trade name GOOFICE®.About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome.Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, among other things: the plans for, or progress, scope, cost, initiation, duration, enrollment, results or timing for availability of results of, development of odevixibat or any other Albireo product candidate or program, including regarding expectations regarding the impact of COVID-19 on our business and our ability to adapt our approach as appropriate; the Phase 3 clinical program for odevixibat in patients with PFIC, the pivotal trial for odevixibat in biliary atresia (BOLD), the planned pivotal trial for odevixibat in Alagille syndrome and Phase 2 trial for elobixibat being conducted through EA Pharma in Japan; the target indication(s) for development or approval, the size, design, population, location, conduct, cost, objective, enrollment, duration or endpoints of any clinical trial, or the timing for initiation or completion of or availability or reporting of results from any clinical trial, including the Phase 3 PFIC trial for odevixibat, and the long-term open-label extension study, the pivotal trial for odevixibat in biliary atresia, the planned pivotal trial for odevixibat in Alagille syndrome; the potential approval and commercialization of odevixibat; discussions with the FDA or EMA regarding our programs; the potential benefits or competitive position of odevixibat, elobixibat, or any other Albireo product candidate or program or the commercial opportunity in any target indication; the potential benefits of an orphan drug designation; the period for which Albireo’s cash resources will be sufficient to fund its operating requirements (runway); or Albireo’s plans, expectations or future operations, financial position, revenues, costs or expenses. Albireo often uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to: negative impacts of the COVID-19 pandemic, including on manufacturing, supply, conduct or initiation of clinical trials, or other aspects of our business; whether favorable findings from clinical trials of odevixibat to date, including findings in indications other than PFIC, will be predictive of results from the trials comprising the Phase 3 PFIC program or any other clinical trials of odevixibat; whether either or both of the FDA and EMA will determine that the primary endpoint for their respective evaluations and treatment duration of the double-blind Phase 3 trial in patients with PFIC are sufficient, even if the primary endpoint is met with statistical significance, to support approval of odevixibat in the United States or the European Union, to treat PFIC, a symptom of PFIC, a specific PFIC subtype(s) or otherwise; the outcome and interpretation by regulatory authorities of the ongoing third-party study pooling and analyzing of long-term PFIC patient data; the timing for initiation or completion of, or for availability of data from, clinical trials of odevixibat, including the trials comprising the Phase 3 PFIC program, the pivotal program in biliary atresia or the planned pivotal program in Alagille syndrome, and the outcomes of such trials; Albireo’s ability to obtain coverage, pricing or reimbursement for approved products in the United States or European Union; delays or other challenges in the recruitment of patients for, or the conduct of, the double-blind Phase 3 trial or other pivotal trials; and Albireo’s critical accounting policies. These and other risks and uncertainties that Albireo faces are described in greater detail under the heading “Risk Factors” in Albireo’s most recent Annual Report on Form 10-K or in subsequent filings that it makes with the Securities and Exchange Commission. As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur. Albireo cautions you not to place undue reliance on any forward-looking statement. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Albireo disclaims any obligation to update any forward-looking statement, except as required by applicable law.Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC, 617-430-7578 Media Contact: Claire LaCagnina, 6 Degrees, 315-765-1462, clacagnina@6degreespr.comSource: Albireo Pharma, Inc.
- 08/18/2020
|
Dupont Capital Management Corp Takes Position in Albireo Pharma Inc (NASDAQ:ALBO)
- Dupont Capital Management Corp purchased a new stake in Albireo Pharma Inc (NASDAQ:ALBO) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 8,966 shares of the biopharmaceutical company’s stock, valued at approximately $238,000. Dupont Capital Management Corp owned approximately 0.06% of Albireo Pharma as of […]
- 08/09/2020
|
Albireo Reports Q2 2020 Financial Results and Provides Business Update
- — Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials — — Enrolled first biliary atresia patients in second odevixibat pivotal study — — Completed two financing transactions to secure cash into beginning of 2022 — — Management to host conference call and webcast today at 10:00 a.m. ET —BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the second quarter ended June 30, 2020.“We are approaching arguably the most important moment in the history of our company having achieved last patient visits in our odevixibat Phase 3 program in PFIC and elobixibat Phase 2 program in NASH,” said Ron Cooper, President and Chief Executive Officer of Albireo. “We eagerly await the topline data in those two trials, while continuing to enroll patients in our precedent setting odevixibat biliary atresia pivotal program (BOLD) and gearing up to initiate a third odevixibat pivotal trial in Alagille syndrome by end of year. With a strong financial foundation and cash runway into the beginning of 2022, we have enabled our continued growth past the planned approval and commercial launch of odevixibat for PFIC, supported additional odevixibat pivotal trials, and advanced development of both elobixibat in NASH and the exciting preclinical programs rounding out our pipeline.”Recent Highlights Odevixibat * Achieved last patient visit in the PEDFIC 1 Phase 3 trial with odevixibat in progressive familial intrahepatic cholestasis (PFIC). Expect topline data to include 62 out of a planned 60 enrolled patients, with no patients lost to follow-up due to COVID-19. Company continues to anticipate topline data in the coming weeks aligned to our mid-2020 guidance, with regulatory approval, issuance of a rare pediatric disease priority review voucher and launch anticipated in H2 2021. * Enrolled first patients in Company’s Phase 3 BOLD study in biliary atresia, a rare pediatric liver disease that is the leading cause of liver transplants among children, and for which there is no approved pharmacological treatment. BOLD is a double-blind, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of odevixibat in children who have biliary atresia and have undergone a Kasai procedure before age three months. The U.S. Food and Drug Administration (FDA) and European Commission have granted orphan designations for odevixibat in the treatment of biliary atresia. * Preparing to initiate clinical trial in Alagille syndrome by the end of 2020, following agreement on the protocol design by U.S. and European regulatory authorities. Topline data expected to be available between the announcement of PFIC and biliary atresia topline results. The FDA and European Commission have granted orphan designations for odevixibat in the treatment of Alagille syndrome. * Launched Expanded Access Program (EAP) for eligible patients with PFIC in the U.S., Canada, Australia and Europe. * Agreed to financial support of a genetic testing program for all types of PFIC and Alagille syndrome at no cost to qualified patients in the U.S. The program builds on Albireo’s commitment to support patients in their journey to diagnosis and treatment of rare pediatric cholestatic liver diseases.Elobixibat * Achieved last patient visit in the Phase 2 trial in nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) designed as a proof of concept to demonstrate a combination of positive trends in liver markers, CV risk factors and favorable GI tolerability. Data will be available for 43 out of 47 patients, as 4 patients were lost to follow-up primarily due COVID-19. Company anticipates topline data in the coming weeks ahead of the odevixibat PEDFIC 1 data. * Company continues to anticipate topline data by the end of the year or early next year in a second Phase 2 study of elobixibat in 100 patients with NASH and NAFLD, conducted through partner EA Pharma in Japan.Early Stage Pipeline * Progressed preclinical development and expect to complete IND-enabling studies in lead preclinical candidate this year. Corporate * Announced two financing transactions: restructured royalty monetization agreement with HealthCare Royalty Partners III, L.P. to receive an additional $15 million in non-dilutive capital for elobixibat in the treatment of chronic constipation in Japan, and an agreement with Hercules Capital, Inc. on a debt facility to provide up to $80 million of new capital with initial draw down of $10 million, resulting in net cash of $24.3 million and extending the cash runway into the beginning of 2022. * Hosted a Key Opinion Leader call with Chad Gwaltney, Ph.D., who discussed key considerations for the design and implementation of clinical outcome assessments, including patient-reported and observer-reported outcomes in PEDFIC 1 & 2\. Dr. Gwaltney provided further background on the PRUCISION measurement tools used in the Phase 3 trials, which were developed rigorously with patients, caregivers, and expert clinicians, as well as in close consultation with the FDA. * Presented at the Jefferies virtual investor conference.Second Quarter 2020 Financial Results * Revenue was $1.9 million for the second quarter of 2020, compared with $1.3 million for the second quarter of 2019. The higher revenue was due to the estimated royalty revenue received from EA Pharma for elobixibat for the treatment of chronic constipation. The royalty revenue is passed on to HealthCare Royalty Partners. * R&D expenses were $18.4 million for the second quarter of 2020, compared with $11.0 million for the second quarter of 2019. The higher expenses were primarily due to program expenses for odevixibat, as well as personnel costs, as the Company continues to develop additional indications for its lead asset. * G&A expenses were $8.5 million for the second quarter of 2020, compared with $5.5 million for the second quarter of 2019. The increase was attributable to personnel and related expenses, as the Company continues to increase its headcount and commercialization readiness expenses. * Net loss for the second quarter of 2020 was $20.6 million, or $(1.38) per share, compared with $16.6 million, or $(1.35) per share for the second quarter of 2019. * Company had cash and cash equivalents at June 30, 2020 of $152.0 million. During the second quarter of 2020, an additional $24.3 million of net cash was received from recently completed non-dilutive financings. As a result, cash and cash equivalents are anticipated to be sufficient into the beginning of 2022.Conference Call As previously announced, Albireo will host a conference call and webcast today, August 6, 2020, at 10:00 a.m. ET. To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13706144. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that participants register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
- 08/06/2020
|
Traders Buy High Volume of Call Options on Albireo Pharma (NASDAQ:ALBO)
- Albireo Pharma Inc (NASDAQ:ALBO) saw unusually large options trading on Monday. Traders purchased 2,232 call options on the stock. This represents an increase of 1,154% compared to the typical daily volume of 178 call options. Several institutional investors have recently bought and sold shares of ALBO. Perceptive Advisors LLC increased its holdings in shares of […]
- 08/05/2020
|
Albireo to Present at the William Blair Biotech Focus Conference 2020
- BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT. The live webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least two weeks following the event.About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC., 212-915-2568 Media Contact: Claire LaCagnina, 6 Degrees, 315-765-1462, clacagnina@6degreespr.com
- 07/30/2020
|
Albireo to Report Q2 2020 Financial Results on August 6
- — Conference call and webcast to be held at 10:00 a.m. ET — BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on August 6, 2020, to provide a business update and review the company’s financial results for the second quarter ended June 30, 2020.To access the live conference call by phone, please dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13706144. A live audio webcast will be accessible from the Media & Investors page of Albireo’s website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 3 months following the event.About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.Investor Contact: Hans Vitzthum, LifeSci Advisors, LLC., 212-915-2568 Media Contact: Claire LaCagnina, 6 Degrees, 315-765-1462, clacagnina@6degreespr.com
- 07/30/2020
|
3 “Strong Buy” Pharma Stocks With Fast-Approaching Catalysts
- Given the widespread market volatility, some investors are seeking refuge in more defensible stocks. However, this certainly doesn’t apply to every Wall Street observer. A select group remains ready to take on some risk, enticed by the possibility of massive returns. Where are they looking for these opportunities? The pharmaceutical industry.The nature of the sector sets names up for impressive upside potential as only a few key events like data readouts and regulatory decisions indicate whether a pharma company will be able to generate essential revenues. As a result, any development can serve as a catalyst that gets the ball rolling, and sends shares either skyrocketing or tumbling downwards. This is what makes investing in pharma stocks such a high stakes game.Understanding the risk involved, we set out to find only the stand-outs in the pharma space, as determined by the analyst community. Looking at three in particular, TipRanks’ database revealed the stocks are getting plenty of love from the Street, enough to score a “Strong Buy” consensus rating, ahead of possible catalysts. Not to mention each ticker offers pretty serious upside potential.Albireo Pharma (ALBO)Through the power of bile acid modulation, Albireo Pharma is developing potential treatment options to improve the lives of people with liver disease. With the company gearing up for an important data readout, several members of the Street think that now could be the time to get in on the action.ALBO is slated to release top-line data from the Phase 3 PEDFIC-1 trial in Q3, which is evaluating its lead candidate, odevixibat. The therapy is an ileal bile acid transporter (IBAT) inhibitor designed as a treatment of progressive intrahepatic cholestasis (PFIC).Ahead of the readout, five-star analyst Ritu Baral likes what she’s seeing. “Top-line data would be a major catalyst to ALBO shares and support both NDA and MAA filings. We see the trial's probability of success at ~60% with ~80% upside to ALBO shares,” the analyst commented. What’s driving her optimistic approach? The data from the Phase 2 study and odevixibat’s targeted mechanism of action.Looking more closely at the available data, in the MAD Phase 2 study, a four-week treatment with odevixibat was able to produce a 61% reduction in serum bile acid (sBA) levels. Additionally, the company has provided “strong data supporting the correlation between reduction in sBA levels and improvement in itch scores.” Baral added, “Odevixibat specifically targets and inhibits IBAT, which should cause a greater increase in bile acid excretion relative to production. We think this mechanism should lead to meaningful improvements in sBA and itch scores in the pivotal Phase 3.” As for institutional investors, they also appear to be optimistic. After surveying 13 institutional investors regarding the upcoming Phase 3 trial, Baral found that “investors are overall bullish on the Phase 3 PEDFIC-1 trial with a majority believing the trial will hit on its itch endpoint (the primary endpoint for FDA review).” That being said, some participants weren’t convinced that odevixibat will show a diarrhea signal. This is problematic as it could hamper commercial uptake within the PFIC population. However, Baral still has high hopes going forward given the promising Phase 2 results.Everything that ALBO has going for it prompted Baral to maintain an Outperform rating and $39 price target. Should the target be met, a twelve-month gain of 54% could be in store. (To watch Baral’s track record, click here) Do other analysts agree with Baral? They do. Only Buy ratings, 5, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $55.25, the average price target implies shares could climb 118% higher in the next year. (See ALBO stock analysis on TipRanks)Homology Medicines (FIXX)Hoping to advance its unique gene editing and gene therapy platform, Homology Medicines believes its assets could potentially cure rare genetic diseases. As the fast-approaching release of clinical data could fuel significant upside, this pharma name is scoring significant attention from the Street.Writing for RBC Capital, analyst Luca Issi acknowledges that there is limited data available, making it difficult to gauge if the Phase 1/2 update, which should come by September at the latest, will be positive. The Phase 1/2 program is assessing its lead asset, a liver-targeting AAVHSC15 vector, in adult phenylketonuria (PKU), a metabolic disease caused by reduced phenylalanine activity that affects 50,000 people globally.Issi tells investors it’s “difficult to pound the table,” given that FIXX only released data for three patients so far. However, based on the $14.77 share price and the fact that the early data “showed a positive trend,” the analyst is on board. “Recall, Dec-19 first look at pheNIX showed no response at low dose (n=2) and one responder at mid-dose. Despite some controversy around baseline vs pre-treatment values, we are encouraged by the early look given concomitant Phe reduction/Tyr boosting, suggesting restoration of metabolic pathway,” he explained.In terms of how many patients will be included in this update, Issi believes there will be an additional one or two patients at the mid-dose and up to three at the high dose. It’s also possible that FIXX will report data from an even higher dose. At the mid-dose, Issi is anticipating a longer patient 3 follow up, a first look at patient 4 (prior data immature) and potentially even data from one additional patient. “At the high dose, which is most important, we are expecting ≤3 patients. Cohort 4 data is also possible (recall FIXX can dose in between mid- and high- dose or go even higher by amending the protocol),” he said.Although the “devil will be in the details,” competing therapy Palynziq’s recent approval suggests that a 50% reduction in Phe is the threshold for success. Not to mention given Palynziq’s shortcomings, “FIXX may revolutionize PKU given potential for one-time functional cure.”Issi added, “Competition is fierce, but FIXX is leading the way (only gene-therapy with clinical data) and capitalizing on first-mover advantage will be key given curative nature of gene therapy depletes the prevalence pool.”With Issi estimating peak sales of $1.1 billion, the deal is sealed. In addition to reiterating an Outperform recommendation, he left the price target at $30. This target implies massive upside potential of nearly 100%.Overall, the bulls have it on this one. Out of 6 total reviews published in the last three months, all 6 analysts rated the stock a Buy. So, FIXX gets a unanimous Strong Buy consensus rating. Given the $33.50 average price target, shares could soar 123% in the next twelve months. (See FIXX stock analysis on TipRanks)Assembly Biosciences (ASMB)Primarily focused on the development of two clinical platforms, a hepatitis B virus (HBV) program and a microbiome program, Assembly Biosciences wants to address the unmet needs of millions of patients around the world. Even before its presentation of updated Phase 2 biomarker data at medical meetings in August and November, this pharma company has already impressed the analyst community.Representing SVB Leerink, analyst Geoffrey Porges calls ASMB a “compelling investment” ahead of the Phase 2 ABI-H0731 biomarker update. ABI-H0731 is its core inhibitor (CI) that was designed as a possible cure for HBV. Citing previously released data, Porges points out the therapy has produced positive results and demonstrated a clean safety profile.While interim data was released back in November 2019, in May 2020, management revealed that since then, approximately two-thirds of the virally suppressed cohort had reached ultra-low/undetectable biomarker levels to meet therapy stopping criteria. Additionally, 80% of the treatment-naïve cohort is set to continue treatment because biomarkers continued to decline. “This tells us that updates at the European Association for the Study of Liver (EASL, August) and the American Association for the Study of Liver Disease (AASLD, November) are likely to be directionally positive, which should draw incremental investor interest ahead of the binary cure event in 1H 2021,” Porges commented.This update could drive upside, but Porges is focused on the cure event in 1H 2021.” He explained, “The pharmaceutical industry’s investment in HBV cures has stalled as progress could not surpass the spontaneous <1%/year cure rate achievable with approved nucleoside reverse transcriptase inhibitors (NRTIs). If initial cures are unlocked with the CI/NRTI combination, then CIs would also become the backbone for future therapies.”To this end, Porges believes “large biopharma companies are very likely to be interested in the potential value generated from treating the 292 million global HBV patient population, which could generate $75 billion in cumulative sales using HCV cure therapies as a proxy.” The analyst also told clients, “As an HBV leader and pureplay during this potential therapeutic breakthrough, we believe ASMB should earn a premium price because it owns the first-to-market and potentially best-in-class CI portfolio.”Based on all of the above, Porges put his stamp of approval on ASMB. Along with his bullish call, he bumped up the price target from $36 to $38. Shares could appreciate by 60%, should the analyst’s thesis play out in the coming months. (To watch Porges' track record, click here)Judging by the consensus breakdown, other analysts also like what they’re seeing. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. The $47.33 average price target puts the upside potential at nearly 100%. (See Assembly stock-price forecast on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/28/2020
|
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
- Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
- 07/26/2020
|
Albireo Pharma Target of Unusually Large Options Trading (NASDAQ:ALBO)
- Albireo Pharma Inc (NASDAQ:ALBO) was the recipient of some unusual options trading on Monday. Investors bought 2,072 put options on the company. This is an increase of approximately 1,401% compared to the average daily volume of 138 put options. Institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in […]
- 07/22/2020
|
Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe
- BOSTON, July 20, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the.
- 07/20/2020
|
Albireo Pharma (NASDAQ:ALBO) Trading 7.5% Higher Following Analyst Upgrade
- Albireo Pharma Inc (NASDAQ:ALBO) shares traded up 7.5% during trading on Friday after HC Wainwright raised their price target on the stock from $62.00 to $64.00. HC Wainwright currently has a buy rating on the stock. Albireo Pharma traded as high as $26.02 and last traded at $25.94, 140,864 shares were traded during trading. An […]
- 07/19/2020
|
Albireo Pharma (ALBO) Initiated with a Buy at H.C. Wainwright - Markets
- H.C. Wainwright analyst Ed Arce initiated coverage with a Buy rating on Albireo Pharma (ALBO – Research Report) today and
- 07/16/2020
|
Galera Phase 2 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
- Galera completed enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. Albireo enrolled the first patient in its Phase 3 clinical trial of Odevixibat.
- 07/15/2020
|
Albireo Pharma (ALBO) Gets a Buy Rating from Wedbush - Markets
- Wedbush analyst Liana Moussatos maintained a Buy rating on Albireo Pharma (ALBO – Research Report) today and set a price
- 07/14/2020
|
Albireo Enrolls First Patient in Phase 3 Clinical Trial of Odevixibat in Biliary Atresia
- — BOLD is first-ever pivotal trial for biliary atresia —— Trial expands odevixibat’s development program into second rare cholestatic liver disease —BOSTON, July 14, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the first patient has been enrolled in the BOLD (Biliary atresia and the use of Odevixibat in treating Liver Disease) global Phase 3 clinical trial of odevixibat, a highly potent and selective inhibitor of the ileal bile acid transporter (IBAT), for the treatment of biliary atresia. There are no approved pharmacological treatments for biliary atresia which is the most common pediatric cholestatic liver disease and the leading cause of pediatric liver transplant across all diseases. BOLD is the largest, prospective intervention trial ever conducted in biliary atresia, expanding the development of odevixibat to a second rare cholestatic liver disease indication. Two clinical sites in the United States are currently active for patient enrollment in the second odevixibat Phase 3 pivotal trial.Biliary atresia is a rare pediatric liver disease with symptoms typically developing about two to eight weeks after birth and no approved pharmacological therapies. Damaged or absent bile ducts outside the liver result in bile and bile acids being trapped inside the liver, quickly resulting in cirrhosis, and even liver failure. The disease impacts an estimated 15,000-20,000 people in the United States and European Union and is the leading cause of liver transplants among children. Odevixibat has received orphan drug designation for biliary atresia in the United States and European Union.“The initiation of the BOLD trial is encouraging progress for biliary atresia patients, their families and clinicians, as it is the first-ever pivotal trial of a pharmacological therapy for this devastating rare disease,” said Saul Karpen, M.D., Ph.D., Pediatric Hepatologist at Children’s Healthcare of Atlanta and lead investigator of the BOLD trial. “There is an incredible unmet need for these patients with biliary atresia, since there are no effective therapies to stem the expected progression of disease. This lack of effective therapeutics leads to the current state of the field where approximately 70 percent of biliary atresia patients will need a liver transplant during childhood. I look forward to seeing how a targeted therapeutic, odevixibat, one that specifically addresses the accumulation of bile acids in the liver, may delay or prevent liver transplant for babies with this serious disease.”BOLD (NCT04336722) is a double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of odevixibat in children who have biliary atresia and have undergone a Kasai procedure before age three months. Children in the treatment arm will receive odevixibat and escalate to 120 μg/kg orally once daily for 24 months. The primary efficacy endpoint is improvement in the proportion of patients who are alive and have not undergone a liver transplant after two years of treatment compared to placebo, and secondary outcome measures include time to onset of any sentinel events, total bilirubin levels and serum bile acid levels. The trial will enroll approximately 200 patients at up to 75 sites globally. “We’re pleased to expand the evaluation of odevixibat into a second pivotal trial with the initiation of the precedent-setting BOLD trial for patients with biliary atresia, the most common rare pediatric liver disease,” said Ron Cooper, President and Chief Executive Officer of Albireo. “We look forward to continuing our work to realize the potential of odevixibat as a much-needed treatment option for patients across multiple cholestatic liver diseases with BOLD and our PEDFIC 1 Phase 3 trial of odevixibat in progressive familial intrahepatic cholestasis, which we continue to expect topline data from in mid-2020.”In addition to the BOLD and PEDFIC 1 trials, Albireo is finalizing a third pivotal trial of odevixibat in Alagille syndrome and anticipates initiating the trial by the end of 2020. About Odevixibat Odevixibat is a product candidate being developed to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome. A highly potent and selective inhibitor of the ileal bile acid transporter (IBAT), odevixibat has minimal systemic exposure and acts locally in the small intestine. Odevixibat is being evaluated in the PEDFIC 1 Phase 3 clinical trial in patients with PFIC (NCT03566238), as well as the BOLD Phase 3 clinical trial in patients with biliary atresia (NCT04336722).The odevixibat PFIC program, or elements of it, have received fast track, rare pediatric disease and orphan drug designations in the United States. In addition, the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to odevixibat for the treatment of Alagille syndrome, biliary atresia and primary biliary cholangitis. The European Medicines Agency (EMA) has granted odevixibat orphan designation, as well as access to the PRIority MEdicines (PRIME) scheme for the treatment of PFIC. Its Pediatric Committee has agreed to Albireo’s odevixibat Pediatric Investigation Plan for PFIC. EMA also has granted orphan designation to odevixibat for the treatment of Alagille syndrome, biliary atresia and primary biliary cholangitis.About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, among other things: the plans for, or progress, scope, cost, initiation, duration, enrollment, results or timing for availability of results of, development of odevixibat, elobixibat or any other Albireo product candidate or program, including regarding expectations regarding the impact of COVID-19 on our business and our ability to adapt our approach as appropriate; the Phase 3 clinical program for odevixibat in patients with PFIC, the pivotal trial for odevixibat in biliary atresia (BOLD), the planned pivotal trial for odevixibat in Alagille syndrome, the Phase 2 clinical trial for elobixibat in NAFLD/NASH, and another Phase 3 trial for elobixibat being conducted by EA Pharma in Japan; the target indication(s) for development or approval, the size, design, population, location, conduct, cost, objective, enrollment, duration or endpoints of any clinical trial, or the timing for initiation or completion of or availability or reporting of results from any clinical trial, including the Phase 3 PFIC trial for odevixibat, and the long-term open-label extension study, the pivotal trial for odevixibat in biliary atresia, the planned pivotal trial for odevixibat in Alagille syndrome, or the Phase 2 trial for elobixibat in NAFLD/NASH; the potential approval and commercialization of odevixibat; discussions with the FDA or EMA regarding our programs; the potential benefits or competitive position of odevixibat, elobixibat, or any other Albireo product candidate or program or the commercial opportunity in any target indication; the potential benefits of an orphan drug designation; the period for which Albireo’s cash resources will be sufficient to fund its operating requirements (runway); or Albireo’s plans, expectations or future operations, financial position, revenues, costs or expenses. Albireo often uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “planned,” “continue,” “guidance,” and similar expressions to identify forward-looking statements.
- 07/14/2020
|
Why Albireo Pharma's (NASDAQ:ALBO) CEO Pay Matters
- This article will reflect on the compensation paid to Ron Cooper who has served as CEO of Albireo Pharma, Inc...
- 07/13/2020
|
Albireo Pharma Inc (NASDAQ:ALBO) Expected to Announce Quarterly Sales of $1.49 Million
- Analysts predict that Albireo Pharma Inc (NASDAQ:ALBO) will report $1.49 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Albireo Pharma’s earnings, with estimates ranging from $1.18 million to $1.65 million. Albireo Pharma reported sales of $1.25 million in the same quarter last year, which […]
- 07/13/2020
|
Are Options Traders Betting on a Big Move in Albireo (ALBO) Stock?
- Investors need to pay close attention to Albireo (ALBO) stock based on the movements in the options market lately.
- 07/10/2020
|
IM Therapeutics Expands Management Team with Appointments of Tom Shea as CFO/COO and Dr. Sarah Bird as VP, Clinical Development
- ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a leading innovator in the field of precision medicine for autoimmune disease, announced today
- 07/08/2020
|
Hedge Funds Souring On Albireo Pharma, Inc. (ALBO)
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- 07/06/2020
|
Why Albireo Pharma (ALBO) Stock Might be a Great Pick
- Albireo Pharma (ALBO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 07/01/2020
|
Albireo Pharma Inc (NASDAQ:ALBO) Stock Holdings Lessened by UBS Group AG
- UBS Group AG reduced its holdings in Albireo Pharma Inc (NASDAQ:ALBO) by 55.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 7,365 shares of the biopharmaceutical company’s stock after selling 9,042 shares during the quarter. UBS Group AG’s holdings in Albireo Pharma were worth […]
- 06/22/2020
|
Albireo Pharma (NASDAQ:ALBO) Trading 5.8% Higher
- Shares of Albireo Pharma Inc (NASDAQ:ALBO) shot up 5.8% during trading on Friday . The stock traded as high as $28.14 and last traded at $27.89, 101,138 shares were traded during trading. An increase of 2% from the average session volume of 98,918 shares. The stock had previously closed at $26.35. Several research firms have […]
- 06/21/2020
|
Bank of New York Mellon Corp Has $733,000 Stake in Albireo Pharma Inc (NASDAQ:ALBO)
- Bank of New York Mellon Corp boosted its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 23.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,744 shares of the biopharmaceutical company’s stock after purchasing an additional 8,429 shares during the quarter. Bank of […]
- 06/20/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xenetic Biosciences
- 06/17/2020
|
Albireo Pharma (ALBO) Received its Third Buy in a Row - Markets
- After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this
- 06/17/2020
|
Analysts' Top Healthcare Picks: Albireo Pharma (ALBO), Monopar Therapeutics Inc (MNPR) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma
- 06/16/2020
|
Albireo to Host Key Opinion Leader Call on Clinical Outcome Assessments
- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a Key Opinion Leader (KOL) call on clinical outcome assessments (COAs) on Tuesday, June 16th at 8:00 am Eastern Time. This call will feature a presentation by KOL Chad Gwaltney, Ph.D. who will discuss key considerations for the design and implementation of COAs, including patient-reported and observer-reported outcomes, in clinical trials. As a key contributor to the development of the PRUCISION pruritus measurement tools used by Albireo in the Phase 3 studies, Dr. Gwaltney will discuss the creation of the careful design of PRUCISION to measure treatment benefits.
- 06/10/2020
|
Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022
- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced it has agreed to terms with Hercules Capital, Inc. (HTGC) on a debt facility to provide up to $80 million of new capital, and will receive $15M under a restructured royalty monetization agreement with HealthCare Royalty Partners (HCR) for elobixibat in the treatment of chronic constipation in Japan. Elobixibat, approved in Japan for the treatment of patients with chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. “These funding arrangements with new and existing partners provide the company additional flexibility and cash runway into the beginning of 2022, past the planned approval and commercial launch of odevixibat for the treatment of progressive familial intrahepatic cholestasis,” said Ron Cooper, President and Chief Executive Officer of Albireo.
- 06/09/2020
|
Albireo to Present at 2020 Jefferies Virtual Healthcare Conference
- BOSTON, May 26, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that.
- 05/26/2020
|
The Consensus EPS Estimates For Albireo Pharma, Inc. (NASDAQ:ALBO) Just Fell Dramatically
- One thing we could say about the analysts on Albireo Pharma, Inc. (NASDAQ:ALBO) - they aren't optimistic, having just...
- 05/12/2020
|
Albireo Pharma, Inc. (NASDAQ:ALBO) Just Reported And Analysts Have Been Cutting Their Estimates
- It's been a good week for Albireo Pharma, Inc. (NASDAQ:ALBO) shareholders, because the company has just released its...
- 05/11/2020
|
Albireo Pharma, Inc. (ALBO) Q1 2020 Earnings Call Transcript
- ALBO earnings call for the period ending March 31, 2020.
- 05/08/2020
|
Recap: Albireo Pharma Q1 Earnings
- Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 60.43% year over year to ($2.23), which may not compared to the estimate of ($1.36).Revenue of $1,549,000 higher by 171.75% from the same period last year, which beat the estimate of $1,030,000.Guidance Albireo Pharma hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 07, 2020View more earnings on ALBOWebcast URL: http://public.viavid.com/player/index.php?id=138368Recent Stock Performance Company's 52-week high was at $38.6952-week low: $11.26Price action over last quarter: Up 3.09%Company Profile Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.See more from Benzinga * Recap: International Seaways Q1 Earnings * Recap: Oaktree Specialty Lending Q2 Earnings * Himax Technologies: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/07/2020
|
Albireo Reports Q1 2020 Financial Results and Provides Business Update
- — Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020 —— First sites initiated for second pivotal trial in biliary atresia —— Management to host.
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
How Does Albireo Pharma, Inc. (NASDAQ:ALBO) Affect Your Portfolio Volatility?
- If you're interested in Albireo Pharma, Inc. (NASDAQ:ALBO), then you might want to consider its beta (a measure of...
- 05/03/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Albireo to Report First Quarter 2020 Financial Results on May 7
- BOSTON, April 30, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- 04/30/2020
|
Albireo Pharma (NASDAQ:ALBO) Raised to Buy at BidaskClub
- Albireo Pharma (NASDAQ:ALBO) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday, BidAskClub reports. Other equities research analysts also recently issued research reports about the company. Cowen reaffirmed a “buy” rating and issued a $39.00 target price on shares of Albireo Pharma in […]
- 04/25/2020
|
Albireo Pharma Inc (NASDAQ:ALBO) Shares Sold by Goldman Sachs Group Inc.
- Goldman Sachs Group Inc. reduced its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 66.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,068 shares of the biopharmaceutical company’s stock after selling 19,993 shares during the period. Goldman […]
- 04/25/2020
|
Needham Maintains Their Buy Rating on Albireo Pharma (ALBO)
- In a report released today, Alan Carr from Needham maintained a Buy rating on Albireo Pharma (ALBO – Research Report),
- 04/14/2020
|
William Blair Sticks to Its Buy Rating for Albireo Pharma (ALBO)
- In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Albireo Pharma (ALBO – Research
- 04/09/2020
|
Man Group plc Sells 98,663 Shares of Albireo Pharma Inc (NASDAQ:ALBO)
- Man Group plc lowered its stake in Albireo Pharma Inc (NASDAQ:ALBO) by 51.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 94,187 shares of the biopharmaceutical company’s stock after selling 98,663 shares during the quarter. Man Group plc owned about 0.74% […]
- 04/08/2020
|
Albireo to Present at 19th Annual Needham Healthcare Conference
- BOSTON, April 07, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- 04/07/2020
|
Albireo Pharma (ALBO) Received its Third Buy in a Row
- After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from William Blair.
- 03/27/2020
|
Albireo Pharma (ALBO) Received its Third Buy in a Row
- After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this
- 03/27/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD
- On track to report topline data mid-2020 BOSTON, March 10, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing.
- 03/10/2020
|
Albireo Pharma, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
- Albireo Pharma, Inc. (NASDAQ:ALBO) last week reported its latest yearly results, which makes it a good time for...
- 03/04/2020
|
H.C. Wainwright Maintains a Buy Rating on Albireo Pharma (ALBO)
- H.C. Wainwright analyst
Ed Arce
maintained a
Buy
rating on Albireo Pharma (
ALBO
–
Research Report
) today and set a price target of
$62.00
. The company’s shares closed last Monday at $24.22.
According to
TipRanks.com
, Arce is a 5-star analyst with
- 03/03/2020
|
Albireo Reports Fourth Quarter and Year-End 2019 Financial Results, and Provides Business Update
- — Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end — — Management to.
- 03/02/2020
|
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
- Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved advantageous for ...
- 02/29/2020
|
Did Changing Sentiment Drive Albireo Pharma's (NASDAQ:ALBO) Share Price Down By 17%?
- Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
- 02/27/2020
|
Albireo Recognizes Rare Disease Day and Supports Global Effort to “Reframe Rare” By Highlighting the Challenges of Cholestatic Liver Disorders
- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced its support for Rare Disease Day 2020 and reaffirms its commitment to patients and families living with biliary atresia (BA), Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC) and other rare cholestatic diseases. Rare Disease Day (www.rarediseaseday.org) was established by EURORDIS in 2008 and takes place on the last day of February each year to raise global awareness of the risk and impact of rare diseases.
- 02/27/2020
|
Albireo to Present at Cowen and Company 40th Annual Health Care Conference
- BOSTON, Feb. 26, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- 02/26/2020
|
Albireo to Report Fourth Quarter and Year-End 2019 Financial Results on March 2
- BOSTON, Feb. 24, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
- 02/24/2020
|
NASH: The Second Wave
- Although the first wave (the companies with drugs at Phase-3) is already at the finish line, the effectiveness indicators of these drugs are far from being stro
- 02/20/2020
|
Albireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares
- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. In addition, the underwriters have exercised in full an option to purchase an additional 285,750 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by Albireo, with gross proceeds to Albireo of approximately $46.0 million and net proceeds of approximately $42.9 million, after deducting underwriting discounts and commissions and estimated offering expenses.
- 02/03/2020
|
The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics ...
- 01/30/2020
|
